• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcarePharmaceuticalsAkari Therapeutics
    Picture of Akari Therapeutics logo

    AKTX — Akari Therapeutics News Story

    $8.000.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    • Market Cap
      $14.00m
    • Enterprise Value
      $7.00m
    • Revenue
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • AKTX Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    AKTX Dividends
    All News

    NASDAQ RESUMED AT 09:35 AM

    Picture of Akari Therapeutics logoAkari Therapeutics
    26/05/2026 14:35
    NASDAQ RESUMED  AT 09:35 AM

    Recent news on Akari Therapeutics

    See all news
    • Brief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models

      18/08/2026 13:56
    • UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101

      13/08/2026 22:33
    • Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary

      13/08/2026 21:50
    • Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview

      07/08/2026 21:57
    • Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics

      21/07/2026 12:30

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.